Leishmania mexicana and Leishmania major: Attenuation of wild-type parasites and vaccination with the attenuated lines

Journal of Infectious Diseases

Volumn 187, Issue 10, 2003, Pages 1662-1668

  Daneshvar, Hamid ^a   Coombs, Graham H ^a   Hagan, Paul ^a   Phillips, R Stephen ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEISHMANIA VACCINE; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; INFECTION RESISTANCE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGE; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ANIMALS; BONE MARROW CELLS; CULTURE MEDIA; FEMALE; GENTAMICINS; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; SKIN; TIME FACTORS; VACCINATION; VACCINES, ATTENUATED;

EID: 0038583505     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374783     Document Type: Article

References (30)

1. Pearson RD, Sousa AQ. Clinical spectrum of leishmaniasis. Clin Infect Dis 1996; 22:1-13.
2. Desjeux P. Leishmania and HIV in gridlock. Publication nos. WHO/CTD/LEISH/98.9, UNAIDS/98.23. Geneva, World Health Organization, 1998.
3. Ivens AC, Smith D. Parasite genome analysis. A global map of the Leishmania major genome: prelude to genomic sequencing. Trans R Soc Trop Med Hyg 1997; 91:111-5.
4. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-54.
5. Sereno D, Guilvard E, Maquaire S, et al. Experimental studies on the evolution of antimony-resistant phenotype during the in vitro life cycle of Leishmania infantum: implications for the spread of chemoresistance in endemic areas. Acta Trop 2001; 80:195-205.
6. Ramirez JR, Gilchrist K, Robledo S, et al. Attenuated Toxoplasma gondii ts-4 mutants engineered to express the Leishmania antigen KMP-11 elicit a specific immune response in BALB/c mice. Vaccine 2002; 20:455-61.
7. Sharifi I, FeKri AR, Aflatonian MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351:1540-3.
8. Rappuoli R, Del Giudice G. Identification of vaccine targets. In: Paoletti LC, McInnes PM, eds. Vaccines: from concept to clinic. Boca Raton, FL: CRC Press, 1999:1-17.
9. Handman E, Hocking RE, Mitchell GF, Spithill TW. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol Biochem Parasitol 1983; 7:111-26.
10. 4+ T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect Immun 1993; 61:5205-13.
11. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase deficiency mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998; 161:6794-800.
12. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995; 92:10267-71.
13. Piedrafita D, Xu D, Hunter D, Harrison RA, Liew FY. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol 1999; 163:1467-72.
14. Schuster FL, Sullivan JJ. Cultivation of clinically significant hemoflagellates. Clin Microbiol Rev 2002; 15:374-89.
15. Bates PA, Tetley L. Leishmania mexicana: induction of metacyclogenesis by cultivation of promastigotes at acidic pH. Exp Parasitol 1993; 76:412-23.
16. Walter F, Vicens Q, Westhof E. Aminoglycoside-RNA interactions. Curr Opin Chem Biol 1999; 3:694-704.
17. Chambers HF. Antimicrobial agents continued - the aminoglycosides. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:1219-38.
18. Berens RL, Brun R, Krassner SM. A simple monophasic medium for axenic culture of hemoflagellates. J Parasitol 1976; 62:360-5.
19. Mallinson DJ, Coombs GH. Biochemical characterisation of the metacyclic forms of Leishmania major and L. mexicana mexicana. Parasitology 1989; 98:7-15.
20. Sutterwala FS, Noel GJ, Clynes R, Mosser MD. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 1997; 185:1977-85.
21. Wolfram M, Fuchs M, Wiese M, Overtath P. Antigen presentation by Leishmania mexicana infected macrophages: activation of helper T cells by model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigotes surface. Eur J Immunol 1996; 26:3153-62.
22. Mottram JC, Souza AE, Hutchison JE, Cater R, Frame MJ, Coombs GH. Evidence from disruption of the lmcp gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl Acad Sci USA 1996; 93:6008-13.
23. Laskay T, Diefenbach A, Rollinghoff M, Solbach W. Early parasite containment is decisive for resistance of Leishmania major infection. Eur J Immunol 1995; 25:2220-31.
24. Modabber F. Experiences with vaccines against cutaneous leishmaniasis of man and mice. Parasitology 1989; 98:S49-60.
25. Liew FY, Donnell CA. Immunology of leishmaniasis. Adv Parasitol 1993; 32:161-259.
26. Hess J, Schaible U, Raupach B, Kaufmann SH. Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv Immunol 2000; 75:1-88.
27. Rivier D, Shah R, Bovay P, Mauel J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasite Immunol 1993; 15:75-84.
28. Gorczynski RM. Immunization of susceptible BALB/c mice against Leishmania braziliensis. I. Resistance induced using as immunogen adherent or nonadherent cells from infected mice. Cell Immunol 1985; 94:1-10.
29. Papadopoulou B, Roy G, Breton M, et al. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun 2002; 70:62-8.
30. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001; 14:229-43.